Edwards Lifesciences

What Edwards Lifesciences does

Edwards Lifesciences is a publicly traded (NYSE: EW) medical device company headquartered in Irvine, California, founded in 1958 (per firmographic data; one source cites 1960) and operating with approximately 16,000 employees worldwide. The company designs, manufactures, and sells transcatheter and surgical heart valve therapies — including the SAPIEN family of transcatheter aortic valve replacement (TAVR) systems, the PASCAL platform for transcatheter edge-to-edge mitral and tricuspid repair, and the EVOQUE transcatheter tricuspid replacement system — alongside surgical valves such as INSPIRIS RESILIA, MITRIS RESILIA, INTUITY Elite, KONECT, and the upcoming TRIFORMIS. Core enabling technology includes the proprietary RESILIA tissue platform, designed to enhance durability and resist calcification, and a portfolio of FDA-cleared and CE-marked devices supported by extensive clinical evidence (PARTNER 3, EARLY TAVR, TRISCEND II, COMMENCE, PROGRESS).

The company's go-to-market is a direct enterprise field sales model targeting large hospital systems and cardiac care centers globally, supplemented by physician training, proctoring, and engagement at major cardiology conferences such as TCT and ESC. Revenue is generated primarily through hardware sales of high-value implantable devices, priced via quotation-based hospital procurement and group purchasing organization contracts, with multi-year contract cadence. Customers include major acute care hospitals with structural heart programs, and the company reports 500,000+ patients treated globally with Edwards valve technologies. In April 2026, Edwards divested its Critical Care business to Becton, Dickinson and Company for $4.2 billion to refocus on structural heart, and has actively used M&A — including JC Medical/J-Valve, Innovalve Bio Medical, and Endotronix — to expand its mitral, tricuspid, and heart failure management portfolios. A new CFO, Doretta Mistras, was appointed in May 2026.

Name

Edwards Lifesciences

Legal name

Edwards Lifesciences Corporation

Website

https://edwards.com

Company type

Public

Founded year

1960

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Edwards Lifesciences (NYSE: EW) is a global medical device company that designs and sells transcatheter and surgical heart valve therapies — including SAPIEN, PASCAL, and EVOQUE platforms — to large hospital systems and cardiac care centers treating structural heart disease.

Ownership category

akta.pro rank

Product category

Structural Heart Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

akta.pro secondary industries

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG), Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH), Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

Keywords

• Transcatheter heart valves
• Structural heart devices
• Surgical heart valves
• Cardiac medical devices
• Heart valve replacement

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Edwards Lifesciences generates revenue primarily through the sale of proprietary medical devices, including transcatheter heart valves, surgical heart valves, and related surgical products. The company operates as a medical device manufacturer with direct sales channels to healthcare facilities.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Edwards Lifesciences designs, manufactures, and sells transcatheter and surgical heart valve replacement and repair devices for the treatment of structural heart disease, including TAVR systems (SAPIEN platform), transcatheter mitral and tricuspid repair/replacement systems (PASCAL, EVOQUE, SAPIEN M3), and surgical heart valves featuring proprietary RESILIA tissue. The portfolio is sold to hospitals, cardiac surgery centers, and interventional cardiologists worldwide and is complemented by the Cordella implantable heart failure management system acquired in 2024.

Product overview

Edwards Lifesciences is the leading global structural heart innovation company offering a comprehensive portfolio of medical devices for transcatheter and surgical heart valve therapies. The company's product portfolio centers on four main platforms: (1) Transcatheter Aortic Valve Replacement (TAVR) featuring the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA systems; (2) Transcatheter Mitral and Tricuspid Technologies (TMTT) including the EVOQUE tricuspid valve, PASCAL/PASCAL Ace mitral repair system, and SAPIEN M3 mitral replacement; (3) Surgical Heart Valves including INSPIRIS RESILIA, MITRIS RESILIA, INTUITY Elite, KONECT, and TRIFORMIS; and (4) Advanced Tissue Technology (RESILIA) for enhanced valve durability. The company also offers implantable heart failure management through the Endotronix/Cordella system acquired in 2024. The portfolio addresses the full continuum of valve disease treatment from transcatheter approaches (TAVR, TEER, valve replacement) to surgical valve replacement and repair, supporting lifetime patient management across aortic, mitral, and tricuspid valve conditions.

Differentiator

Problem solved

Functional benefit

Brands

• SAPIEN: Transcatheter aortic valve replacement platform including SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN M3 systems
• PASCAL
• EVOQUE
• RESILIA
• INSPIRIS
• MITRIS
• Cordella

Products and services

• SAPIEN 3 Transcatheter aortic valve replacement (TAVR) system for treatment of severe aortic stenosis, featuring a balloon-expandable design with cobalt-chromium frame. Sold to hospitals and cardiac care centers for use by interventional cardiologists and cardiac surgeons.
• SAPIEN 3 Ultra Enhanced version of the SAPIEN 3 TAVR system with improved delivery system and expanded indications including FDA approval for asymptomatic severe aortic stenosis patients based on EARLY TAVR study.
• SAPIEN 3 Ultra RESILIA SAPIEN 3 Ultra platform featuring RESILIA tissue technology, a proprietary advanced tissue designed to enhance durability and resist calcification in transcatheter heart valves.
• SAPIEN M3 Transcatheter mitral valve replacement system for treatment of mitral annular calcification, FDA-approved in late 2025 and expanding Edwards' mitral portfolio in the U.S. for patients not well-suited for mitral TEER.
• EVOQUE Tricuspid Valve Replacement System Transcatheter tricuspid valve replacement system for treatment of severe tricuspid regurgitation, FDA-approved and launched in the U.S. and Europe with two-year TRISCEND II trial data demonstrating significantly lower all-cause mortality and near elimination of tricuspid regurgitation.
• PASCAL / PASCAL Ace Repair System Transcatheter edge-to-edge repair (TEER) technology for treatment of mitral regurgitation, featuring a unique design with independent leaflet capture and spacing capabilities. PASCAL Precision is the next-generation system expected in Q4 2026.
• INSPIRIS RESILIA Surgical Aortic Valve Surgical aortic bioprosthetic valve featuring RESILIA tissue technology with 10-year COMMENCE trial data demonstrating 97.9% freedom from structural valve deterioration and 97.8% freedom from reoperation.
• MITRIS RESILIA Surgical Mitral Valve Surgical mitral valve replacement system featuring RESILIA tissue technology for patients whose mitral valvular disease warrants replacement of their natural or previously placed prosthetic valve.
• INTUITY Elite Surgical Aortic Valve Surgical aortic valve system with rapid-deployment features designed to facilitate faster procedures and improved outcomes in aortic valve replacement.
• KONECT Aortic Valved Conduit Aortic valved conduit that facilitates Bentall procedures for patients in need of aortic root replacement, recently launched in Europe with strong adoption.
• TRIFORMIS Surgical Tricuspid Valve Surgical tricuspid valve replacement system expected to launch in second half of 2026, expanding Edwards' portfolio in surgical tricuspid therapies.
• Cordella Heart Failure Management System Implantable heart failure management system acquired by Edwards Lifesciences in 2024 through acquisition of Endotronix, providing pulmonary artery pressure-guided therapy for chronic heart failure management.
• J-Valve System Transcatheter aortic valve system for treatment of severe aortic regurgitation, acquired by Edwards Lifesciences through the purchase of JC Medical from Genesis Medtech in August 2024.

Quantifiable outcome

• 500,000+ patients treated with Edwards heart valve technologies globally
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered supporting and strategic.

• PhilipssupportingTechnology or IntegrationEdwards Lifesciences collaborated with Philips to integrate AI-powered DeviceGuide software for mitral valve repair procedures, enhancing procedural guidance and planning capabilities for physicians performing transcatheter mitral valve interventions.
• Genesis Medtech (JC Medical)strategicStrategic or Co-development PartnerEdwards Lifesciences acquired JC Medical from Genesis Medtech Group, including the J-Valve System for transcatheter aortic valve replacement, expanding Edwards' product portfolio in the aortic valve space.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Stryker: Stryker is a broad medical device incumbent with significant presence in hospital surgical and interventional settings. While not a direct valve competitor, it shares Edwards' hospital procurement customers and competes for capital equipment and procedural suite spending in cardiac surgery.
• Boston Scientific: Boston Scientific is a broad cardiovascular incumbent whose Watchman LAAC device competes with Edwards' planned 2026 LAAC launch and whose cardiology franchise overlaps with Edwards' structural heart hospital call points. It is a relevant competitor as Edwards expands beyond valves into atrial fibrillation-adjacent therapies.
• Johnson & Johnson (Janssen / J&J MedTech): J&J is a broad incumbent in interventional cardiology and cardiovascular devices and acquired Shockwave Medical, expanding its cardiovascular portfolio that overlaps with Edwards' hospital call points. It is a relevant competitive threat as a diversified incumbent with structural heart ambitions.

Emerging players

• CroíValve: CroíValve is an early-stage developer of transcatheter tricuspid coaptation/valve technologies, directly competing in the same structural heart tricuspid space that Edwards' EVOQUE system addresses. It is an emerging European player in the same target indication.
• JenaValve Technology: JenaValve is an emerging transcatheter aortic valve developer focused on aortic regurgitation, the specific asset Edwards tried (and was blocked by the FTC) to acquire. It competes directly with Edwards' J-Valve (via JC Medical) in the AR indication.
• Innoventric: Innoventric is an emerging Israeli company developing transcatheter tricuspid valve technologies, overlapping with Edwards' EVOQUE and PASCAL tricuspid programs. It is a relevant emerging competitor in the same transcatheter tricuspid indication space.

Direct peers

• Artivion: Artivion (formerly CryoLife) is a focused competitor in surgical heart valves, aortic stent grafts, and tissue-preserved valves, overlapping directly with Edwards' surgical heart valve portfolio (INSPIRIS, MITRIS) and competing in the same hospital cardiac surgery accounts.
• LivaNova: LivaNova manufactures heart valves (including sutureless and tissue valves) and cardiopulmonary products, directly competing with Edwards in the surgical heart valve space and adjacent cardiac surgery disposables used by the same surgical teams.
• Medtronic: Medtronic is Edwards' closest direct competitor in transcatheter aortic valves via the Evolut TAVR platform and competes across structural heart. Both companies sell TAVR systems to the same hospital cardiology and cardiac surgery customers with overlapping clinical evidence and FDA-labeled indications.
• Abbott: Abbott competes with Edwards across structural heart via MitraClip and TriClip (TEER) and the Tendyne transcatheter mitral replacement system, plus Amulet for LAAC. It serves the same interventional cardiology customers and is Edwards' principal rival in mitral and tricuspid repair/replacement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/edwards-lifesciences
• Facebookfacebook.com/143318615703224
• Instagraminstagram.com/edwardslifesciences
• YouTubeyoutube.com/user/EdwardsGlobal
• Xx.com/edwardslifesci

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A16 records

Investments13 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edwards Lifesciences